Browsing by Author "Aydin D."

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Effects of non-dependent lung oxygen insuffation on oxygenation and respiratory mechanics during one-lung ventilation in patients with stage II COPD
    (Turkish Anaesthesiology and Intensive Care Society, 2015) Öztürk T.; Aydin D.; Yaldiz S.; Yuncu G.; Atay A.; Savaci S.
    Introduction: The aim of this study was to investigate the changes on oxygenation, shunt ratio and respiratory mechanics of 6 L/min oxygen insuffation to the non-dependent lung, while extrinsic PEEP (PEEPe, equivalent to the patient's PEEPi) was being applied to the dependent lung in patients undergoing lung surgery. Material and Methods: Patients with stage II COPD undergoing elective lung surgery (n=22) were intubated with a doublelumen endobronchial tube and performed a PA catheterization. One lung ventilation settings were: tidal volume 6 ml/kg, 12 breaths/min, and I: E ratio 1: 2. Procedure was performed in four sequential periods (each period continued for 15 minutes): After frst stabilization period (PEEP0-1), PEEPe (at the level of intrinsic PEEP, PEEPi) was applied in the dependent lung while the non-dependent lung was exposed to air. After second stabilization period (PEEP0-2), the non-dependent lung received 6 L/min oxygen (O2) through a catheter placed into the tube while PEEPe (at the level of PEEPi) was applied in the dependent lung (PEEPe+O2). At the end of each 15 minute period, haemodynamic data, lung compliance (C), airway resistance (R), and PEEPi were recorded and blood gas samples were obtained. Results: PaO2 was signifcantly higher during the PEEPe+O2 period (p<0.001), while Qs/Qt was signifcantly lower in the PEEPe+O2 period when compared with the PEEPe period (p<0.0001). Compliance increased signifcantly during PEEPe compared to PEEP0-1 (p<0.05). Discussion and Conclusion: The insuffation of oxygen to the non-dependent lung with application of PEEPe-equivalent to the patient's PEEPi - to the dependent lung increased oxygenation and decreased Qs/Qt in patients with moderate COPD. We recommend this simple and useful method which does not need extra equipment.
  • No Thumbnail Available
    Item
    Neurological outcome after cardiac arrest: A prospective study of the predictive ability of prognostic biomarkers neuron-specific enolase, glial fibrillary acidic protein, S-100B, and procalcitonin
    (Turkiye Klinikleri Journal of Medical Sciences, 2016) Ok G.; Aydin D.; Erbüyün K.; Gürsoy C.; Taneli F.; Bilge S.; Dinç Horasan G.
    Background/aim: Factors affecting neurological outcome and the usefulness of neuron-specific enolase (NSE), S-100B, glial fibrillary acidic protein (GFAP), and procalcitonin (PCT) in predicting neurological outcomes were assessed in patients who survived at least 24 h after cardiopulmonary resuscitation (CPR). Materials and methods: Thirty successfully resuscitated cardiac arrest patients were included in this prospective clinical study. The initial cardiac arrest rhythm, duration of CPR, return of spontaneous circulation time, administered doses of adrenaline, base excess, blood sugar, and hemodynamic parameters were recorded. Patients with Glasgow Outcome Scale (GOS) scores of 1–3 were defined as Group I and patients with GOS scores of 4–5 were defined as Group II. Serum NSE, GFAP, S-100B, and PCT levels were compared between the two groups shortly after CPR (hour 0) and at hours 12 and 24 of the postresuscitation period. Results: Serum S-100B was significantly higher (P = 0.009) in Group II immediately after CPR. Serum S-100B and NSE after CPR at hours 0, 12, and 24 were significantly lower in patients who survived to hospital discharge. Serum PCT at hours 12 and 24 and serum S-100B after CPR at 0, 12, and 24 h reached 94.7% sensitivity. Serum NSE, GFAP, S-100B, and PCT specificities were lower than 50%. Conclusion: In predicting neurological outcomes, serum S-100B has high sensitivity and low specificity immediately after CPR. © TÜBİTAK.
  • No Thumbnail Available
    Item
    Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology)
    (Verduci Editore, 2016) Süner A.; Aydin D.; Hacioǧlu M.B.; Doǧu G.G.; Imamoǧlu G.I.; Menekşe S.; Pilanci K.N.; Yazici Ö.K.; Koca D.; Karaaǧaç M.; Akyol M.; Akman T.; Ergen S.; Avci N.; Kaçan T.; Bozkurt O.; Kefeli U.; Urakçi Z.; Araz M.; Arpaci E.; Harputlu H.; Sevinç A.
    OBJECTIVE: Prostate cancer is among the most common cancers in males. Prostate cancer is androgen dependent in the beginning, but as time progresses, it becomes refractory to androgen deprivation treatment. At this stage, docetaxel has been used as standard treatment for years. Cabazitaxel has become the first chemotherapeutic agent which has been shown to increase survival for patients with metastatic Castrate Resistant Prostate Cancer (mCRPC) that progresses after docetaxel. Phase 3 TROPIC study demonstrated that cabazitaxel prolongs survival. PATIENTS AND METHODS: In this study, we evaluated a total of 103 patients who took cabaz-itaxel chemotherapy for mCRPC diagnosis in 21 centers of Turkey, retrospectively. This study included patients who progressed despite doc-etaxel treatments, had ECOG performance score between 0-2, and used cabazitaxel treatment. Patients received cabazitaxel 25 mg/m2 at every 3 weeks, and prednisolone 5 mg twice a day. RESULTS: Median number of cabazitaxel cures was 5.03 (range: 1-17). Cabazitaxel response evaluation detected that 34% of the patients had a partial response, 22.3% had stable disease and 32% had a progressive disease. Grade 3-4 hema-tological toxicities were neutropenia (28.2%), neutropenic fever (14.5%), anemia (6.7%), and thrombocytopenia (3.8%). In our study, median progression-free survival (PFS) was 7.7 months and overall survival (OS) was 10.6 months. CONCLUSIONS: This study reflects toxicity profile of Turkish patients as a Caucasian race. We suggest that cabazitaxel is a safe and effective treatment option for mCRPC patients who progress after docetaxel. Moreover, ethnicity may play important roles both in treatment response and in toxicity profile.
  • No Thumbnail Available
    Item
    Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    (Newlands Press Ltd, 2023) Kahraman S.; Erul E.; Seyyar M.; Gumusay O.; Bayram E.; Demirel B.C.; Acar O.; Aksoy S.; Baytemur N.K.; Sahin E.; Cabuk D.; Basaran G.; Paydas S.; Yaren A.; Guven D.C.; Erdogan A.P.; Demirci U.; Yasar A.; Bayoglu İ.V.; Hizal M.; Gulbagci B.; Paksoy N.; Davarci S.E.; Yilmaz F.; Dogan O.; Orhan S.O.; Kayikcioglu E.; Aytac A.; Keskinkilic M.; Mocan E.E.; Unal O.U.; Aydin E.; Yucel H.; Isik D.; Eren O.; Uluc B.O.; Ozcelik M.; Hacibekiroglu I.; Aydiner A.; Demir H.; Oksuzoglu B.; Cilbir E.; Cubukcu E.; Cetin B.; Oktay E.; Erol C.; Okutur S.K.; Yildirim N.; Alkan A.; Selcukbiricik F.; Aksoy A.; Karakas Y.; Ozkanli G.; Duman B.B.; Aydin D.; Dulgar O.; Er M.M.; Teker F.; Yavuzsen T.; Aykan M.B.; Inal A.; Iriagac Y.; Kalkan N.O.; Keser M.; Sakalar T.; Menekse S.; Kut E.; Bilgin B.; Karaoglanoglu M.; Sunar V.; Ozdemir O.; Turhal N.S.; Karadurmus N.; Yalcin B.; Nahit Sendur M.A.
    Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference. © 2023 Future Medicine Ltd.
  • No Thumbnail Available
    Item
    Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study
    (BioMed Central Ltd, 2024) Kahraman S.; Hizal M.; Demirel B.C.; Guven D.C.; Gumusay O.; Uluc B.O.; Bayram E.; Gulbagci B.; Yasar A.; Davarci S.E.; Mocan E.E.; Acar O.; Isik D.; Aydin E.; Karakas Y.; Ozcelik M.; Keser M.; Okutur S.K.; Eren O.; Menekse S.; Aydin D.; Yilmaz F.; Dogan O.; Ozkanli G.; Yucel H.; Sunar V.; Aykan M.B.; Ozdemir O.; Duman B.B.; Keskinkilic M.; Sakalar T.; Inal A.; Karaoglanoglu M.; Aksoy A.; Er M.M.; Turhal N.S.; Kalkan N.O.; Sendur M.A.N.
    Highly selective inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6is) have emerged as a standart of care for first- and second-line therapies in combination with endocrine therapy (ET) for HR+/HER2- metastatic breast cancer (MBC) patients. It has been reported that combination therapy is more effective than ET alone and is safe in elderly patients as well as young patients. Nevertheless, elderly and very old patients with HR+/HER2-MBC treated with CDK4/6 inhibitor (CDK4/6i) combinations are relatively underrepresented in randomized controlled trials. To contribute to the literature, we investigated the real-world efficacy, factors associated with survival and the rates of adverse events (AEs) of the treatment with palbociclib or ribociclib plus ET in the HR+/HER2- MBC patient cohort over the age of 65 for age subgroups. In this retrospective study, 348 patients were divided into subgroups: 65–69 years old, 70–79 years old and 80 years and older. Median PFS (mPFS) for whole group was 18.3 (95% CI,14.3–22.3) months. There was no significant difference in mPFS between age groups (p = 0.75). The estimated median OS (mOS) was 39.5 (95% CI, 24.9–54.1) months and there was no significant difference between age groups (p = 0.15). There was a meaningfull numerical difference that did not reach statistical significance in patients who received CDK4/6i treatment as the first line for MBC. Grade 3–4 AEs were reported in 42.7% for the entire group, and neutropenia was the most common (37.3%). It can be concluded that combination therapy with palbociclib or ribociclib with an ET partner has similar efficacy and is safe among subgroups of older patients diagnosed with HR+/HER2-MBC. © The Author(s) 2024.